Metraipolis › archive › dc_ecdcc0843c03

Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41180696
DOI
10.1097/ms9.0000000000003933
License (as archived)
solo-consultazione
Archived
2026-11-09T19:33:56.124Z
SHA-256 of the archived text
c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c
Stable URL of this page
https://metraipolis.com/documento/dc_ecdcc0843c03

How to cite

Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696 — Europe PMC (en), https://europepmc.org/article/MED/41180696 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ecdcc0843c03 (Metraipolis archive dc_ecdcc0843c03, sha256 c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c)
BibTeX
@misc{dcecdcc0843c03,
  title = {Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid) — Europe PMC PMID:41180696},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41180696},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ecdcc0843c03; sha256 c94d306da1b2c63a6d3e62cfbecf5b117d3a65f87255d16a1f6e0e4fd30d948c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41180696. Agents can read the archived copy with the MCP tool read_document.